A phase II study of lenalidomide alone in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes with chromosome 5 abnormalities.

Clinical Lymphoma, Myeloma & Leukemia
Yiming ChenGautam Borthakur

Abstract

This phase II study assessed the efficacy and safety of lenalidomide in patients with relapsed/refractory acute myeloid leukemia (N = 18) and high-risk myelodysplastic syndrome (N = 9) with chromosome 5 abnormalities. The overall complete remission rate with or without platelet recovery was 7% (2/27). Activity of lenalidomide was limited to patients with noncomplex cytogenetics. Lenalidomide is effective in low-risk myelodysplastic syndromes (MDS) with deletion 5q. We conducted a phase II study to evaluate the safety and efficacy of lenalidomide in patients with relapsed/refractory acute myeloid leukemia (AML) and high-risk MDS with any chromosome 5 abnormality. Eighteen adults with AML and 9 with high-risk MDS were enrolled. Lenalidomide was given orally at doses 5 to 25 mg daily for 21 days of a 28-day cycle until disease progression or unacceptable adverse event. Median age for all 27 patients was 64 years (range, 39-88 years) with a median of 2 previous therapies (range, 1-6 lines). Two patients (7%) with AML and 5q deletion and +8 cytogenetic abnormality in 2 separate clones achieved complete remission (CR) or CR without platelet recovery (CRp). Response durations were 4 and 6 months, respectively. No responses were seen i...Continue Reading

References

Dec 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards
Feb 11, 2005·The New England Journal of Medicine·Alan ListJerome B Zeldis
Oct 6, 2006·The New England Journal of Medicine·Alan ListUNKNOWN Myelodysplastic Syndrome-003 Study Investigators
Jan 19, 2007·Leukemia·J E LancetL C Moscinski
Oct 2, 2007·Current Opinion in Oncology·Jose Ortega, Alan List
Nov 23, 2007·The New England Journal of Medicine·Alan F List
Aug 14, 2009·Journal of Hematology & Oncology·Venumadhav KotlaAmit Verma

❮ Previous
Next ❯

Citations

Mar 20, 2014·Current Hematologic Malignancy Reports·Amir T Fathi, Yi-Bin Chen
Jan 16, 2013·Expert Opinion on Investigational Drugs·Yiming Chen, Gautam Borthakur
Feb 1, 2014·Oncoimmunology·Michaela SemeraroLorenzo Galluzzi
May 2, 2015·Journal of Clinical Medicine·Nestor R RamosChristopher S Hourigan
Oct 23, 2016·Clinical Lymphoma, Myeloma & Leukemia·Mona HassaneinRiad El Fakih
Oct 19, 2016·Leukemia Research Reports·Michael MedingerJakob Passweg
Jul 12, 2017·Leukemia & Lymphoma·Brandon KremerStephen J Schuster
May 24, 2018·Cardiovascular & Hematological Disorders Drug Targets·Ota Fuchs
Mar 26, 2014·Current Opinion in Oncology·Laurent Plawny, Fernand Ries
Jul 4, 2018·Frontiers in Oncology·Roberta KiffinAnna Martner
Sep 10, 2020·Cancers·Antonio PiccolomoFrancesco Albano

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.